Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial

Journal:
The Lancet
Published:
Affiliations:
22
Authors:
84
Institutions Authors Share
Global Antibiotic Research and Development Partnership (GARDP), Switzerland
4.047619
0.16
Innoviva Specialty Therapeutics, United States of America (USA)
3.047619
0.12
The University of Alabama at Birmingham (UAB), United States of America (USA)
2.047619
0.08
South African Medical Research Council (SAMRC), South Africa
2.047619
0.08
LSU Health Sciences Center New Orleans (LSUHSC-NO), United States of America (USA)
1.047619
0.04
University of the Witwatersrand, Johannesburg (Wits University), South Africa
1.047619
0.04
San Francisco Department of Public Health (SFDPH), United States of America (USA)
1.047619
0.04
University of Cape Town (UCT), South Africa
1.047619
0.04
Indiana University (IU), United States of America (USA)
1.047619
0.04
Plus-Project, United Kingdom (UK)
1.047619
0.04
Setshaba Research Centre (SRC), South Africa
1.047619
0.04
Institute of HIV Research and Innovation (IHRI), Thailand
1.047619
0.04
University of Washington (UW), United States of America (USA)
1.047619
0.04
Institute of Tropical Medicine (ITM), Belgium
1.047619
0.04
Department of Disease Control, Thailand Ministry of Public Health, Thailand
1.047619
0.04
WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections, Sweden
0.547619
0.02
UCL, United Kingdom (UK)
0.547619
0.02
Public Health Service Amsterdam (GGD), Netherlands
0.297619
0.01
Amsterdam UMC, Location AMC, Netherlands
0.297619
0.01
Amsterdam Institute for Global Health and Development (AIGHD), Netherlands
0.297619
0.01
Amsterdam Institute for Infection and Immunity and Infectious Diseases, Netherlands
0.297619
0.01